Ask OpenScientist

Ask a research question about Postcricoid Region Cancer. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

0
Mappings
0
Definitions
0
Inheritance
4
Pathophysiology
1
Histopathology
4
Phenotypes
9
Pathograph
2
Genes
3
Treatments
0
Subtypes
0
Differentials
0
Datasets
2
Trials
0
Models
1
Deep Research

Pathophysiology

4
Malignant Transformation of Postcricoid Squamous Epithelium
Squamous epithelial cells in the postcricoid hypopharynx undergo malignant transformation, with increased proliferation and acquisition of invasive behavior.
squamous epithelial cell link
DNA damage response link ⚠ ABNORMAL cell population proliferation link ↑ INCREASED
hypopharynx link
Show evidence (1 reference)
DOI:10.1055/s-0042-1759504 SUPPORT Human Clinical
"Squamous cell carcinoma is the most common histological type."
Supports squamous epithelial malignant transformation as the dominant histologic pattern for hypopharyngeal cancers.
Local Invasion and Metastatic Spread
Tumor extension through the hypopharyngeal wall and spread to nodal or distant sites drives staging, prognosis, and multimodality treatment selection.
cell migration link ↑ INCREASED
hypopharynx link
Show evidence (2 references)
DOI:10.1055/s-0042-1759504 SUPPORT Human Clinical
"Imaging also plays a major role in its staging, including local disease extent, nodal and distant metastatic status, as well as to assess response to therapy."
Supports local extension, nodal spread, and distant metastatic status as core hypopharyngeal cancer disease behaviors.
DOI:10.3390/jpm14101048 PARTIAL Other
"The review focuses on indicators, including PD-L1, CTLA-4, and tumor mutational burden (TMB) in predicting immunotherapy responses, highlighting recent developments in our understanding of the intricate interactions between tumor genetics and the immune milieu."
This broader laryngeal/head-and-neck squamous cancer review supports checkpoint-relevant immune biology as a treatment-selection mechanism near the hypopharyngeal/postcricoid disease space.
Adaptive Immune Resistance
Postcricoid and hypopharyngeal squamous tumors can be treated with PD-1 pathway blockade in chemoimmunotherapy protocols, reflecting checkpoint- mediated suppression of antitumor T-cell activity rather than direct targeting of invasion alone.
negative regulation of T cell mediated immunity link ↑ INCREASED
Show evidence (2 references)
PMID:38762484 SUPPORT Other
"However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression."
Supports PD-1/PD-L1 axis exploitation as an adaptive immune resistance mechanism across cancers.
DOI:10.3390/jpm14101048 PARTIAL Other
"The review focuses on indicators, including PD-L1, CTLA-4, and tumor mutational burden (TMB) in predicting immunotherapy responses, highlighting recent developments in our understanding of the intricate interactions between tumor genetics and the immune milieu."
Supports checkpoint-relevant immune biomarkers in an adjacent head-and-neck squamous cancer setting; applied conservatively because it is not postcricoid-subsite specific.
T Cell Exhaustion and Immune Escape
Suppressed tumor-infiltrating T cells can lose effective cytokine production and cytolytic activity, allowing immune escape within the tumor microenvironment.
exhausted T cell link
exhausted T cell differentiation link ↑ INCREASED
Show evidence (1 reference)
PMID:26086965 SUPPORT Other
"The exhausted T cells in the tumor microenvironment show overexpressed inhibitory receptors, decreased effector cytokine production and cytolytic activity, leading to the failure of cancer elimination."
Supports exhausted T-cell immune escape as a downstream checkpoint-related tumor microenvironment state.

Histopathology

1
Squamous Cell Carcinoma VERY_FREQUENT
Squamous cell carcinoma is the dominant histologic type for hypopharyngeal cancers and is the expected histology for most postcricoid primary tumors.
Show evidence (1 reference)
DOI:10.1055/s-0042-1759504 SUPPORT Human Clinical
"Squamous cell carcinoma is the most common histological type."
Directly supports squamous carcinoma as the common histology in hypopharyngeal cancer.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Referential integrity issues (1):
  • Target 'Airway and Voice Dysfunction' (from 'Local Invasion and Metastatic Spread') not found in named elements
Pathograph: causal mechanism network for Postcricoid Region Cancer Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

4
Blood 1
Anemia in Plummer-Vinson Syndrome Risk Context OCCASIONAL Anemia (HP:0001903)
Show evidence (1 reference)
PMID:31417270 SUPPORT Human Clinical
"Plummer-Vinson syndrome is a rare condition associated with dysphagia, iron deficiency, and esophageal webs."
Supports anemia/iron deficiency as part of the postcricoid-relevant Plummer-Vinson risk context.
Digestive 1
Dysphagia FREQUENT Dysphagia (HP:0002015)
Show evidence (1 reference)
PMID:38711727 SUPPORT Human Clinical
"A 33-year-old female presented at a tertiary care hospital in Western India with hoarseness of voice, difficulty in swallowing, productive cough, and neck pain for two months with an abrupt increase in the severity of all symptoms in two days."
This post-cricoid growth case directly supports dysphagia as a presenting manifestation.
Respiratory 1
Respiratory Failure or Airway Compromise OCCASIONAL Respiratory insufficiency (HP:0002093)
Show evidence (1 reference)
PMID:19078805 SUPPORT Human Clinical
"Computed tomography of his neck identified a postcricoid squamous cell carcinoma, which was causing bilateral vocal cord paralysis."
Supports airway and vocal cord involvement as a severe manifestation of postcricoid carcinoma.
Voice 1
Hoarse Voice FREQUENT Hoarse voice (HP:0001609)
Show evidence (1 reference)
PMID:19078805 SUPPORT Human Clinical
"This report describes a 73-year-old man who had a 10-month history of progressive hoarseness, dysphagia, and respiratory failure."
This postcricoid carcinoma case supports hoarseness and swallowing symptoms as presenting features.
🧬

Genetic Associations

2
Somatic head and neck squamous carcinoma alterations
Show evidence (1 reference)
PMID:39219259 PARTIAL Human Clinical
"Comprehensive genomic, transcriptomic, metabolomic, microbiome and proteomic analyses allow researchers to identify important biological markers such as genetic alterations, gene expression signatures and protein markers that drive HNSCC tumours."
Supports molecular alteration as relevant in the broader HNSCC family; the assertion is deliberately broad because the cited evidence is not postcricoid-subsite specific.
TP53 alteration in head and neck squamous carcinoma
Show evidence (1 reference)
PMID:25631445 PARTIAL Human Clinical
"Smoking-related HNSCCs demonstrate near universal loss-of-function TP53 mutations and CDKN2A inactivation with frequent copy number alterations including amplification of 3q26/28 and 11q13/22."
Supports TP53 as a major altered gene in broader HNSCC; marked PARTIAL because the TCGA cohort is not specific to the postcricoid subsite.
💊

Treatments

3
Radical Radiotherapy for Early-Stage Hypopharyngeal SCC
Action: radiation therapy MAXO:0000014
Organ-preserving radiotherapy is an evidence-supported option for selected early-stage hypopharyngeal SCC, including small postcricoid-region subsets.
Mechanism Target:
INHIBITS Malignant Transformation of Postcricoid Squamous Epithelium — Definitive radiotherapy targets proliferating malignant squamous tumor cells at the primary site.
Show evidence (1 reference)
PMID:38719981 SUPPORT Human Clinical
"This study supports radical radiotherapy as an effective approach for optimal tumor control in patients with early stage HSCC."
Supports radical radiotherapy as an organ-preserving option for early-stage hypopharyngeal SCC.
Surgery-Based Therapy for Resectable Hypopharyngeal Carcinoma
Action: surgical procedure MAXO:0000004
Surgery-based therapy, often followed by adjuvant radiotherapy with or without chemotherapy depending on stage and risk features, is used for resectable hypopharyngeal/postcricoid disease.
Mechanism Target:
INHIBITS Local Invasion and Metastatic Spread — Resection removes locally invasive tumor, with adjuvant therapy selected for residual local, nodal, or metastatic risk.
Show evidence (2 references)
PMID:36937435 SUPPORT Human Clinical
"SBT can obtain significant survival benefits when compared with definitive CRT for the whole cohort of patients."
Supports surgery-based therapy as an important treatment modality for hypopharyngeal carcinoma.
DOI:10.1055/s-0042-1759504 SUPPORT Human Clinical
"Advanced disease is treated with multimodality of either chemoradiotherapy or surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy."
Supports multimodality treatment for advanced hypopharyngeal cancer.
Induction Chemoimmunotherapy for Locally Advanced Hypopharyngeal SCC
Action: pharmacotherapy MAXO:0000058
Agent: camrelizumab docetaxel cisplatin capecitabine
Phase II data support induction camrelizumab plus modified TPF as an emerging organ-preservation strategy for locally advanced hypopharyngeal squamous cell carcinoma, with surgery and adjuvant treatment reserved for non-responders in the studied protocol.
Mechanism Target:
INHIBITS Adaptive Immune Resistance — Camrelizumab-containing induction therapy includes PD-1 pathway blockade, linking this regimen to checkpoint-mediated immune escape rather than to local invasion alone.
MODULATES Local Invasion and Metastatic Spread — The combined chemotherapy and immunotherapy regimen aims to shrink locally advanced tumor and select patients for organ-preserving therapy versus surgery.
Show evidence (2 references)
PMID:38898018 SUPPORT Human Clinical
"This phase II trial aimed to determine the efficacy and safety of induction chemoimmunotherapy of camrelizumab plus modified TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698)."
Supports chemoimmunotherapy as an emerging treatment strategy for locally advanced hypopharyngeal SCC.
PMID:38898018 SUPPORT Human Clinical
"After induction therapy, the ORR was 82.4% (42/51), meeting the prespecified endpoint."
Provides trial outcome evidence for response after induction chemoimmunotherapy.
🌍

Environmental Factors

2
Tobacco and alcohol exposure
exposure to tobacco smoking link
Tobacco and alcohol exposure are established risk factors across head and neck squamous cell carcinomas and are relevant to hypopharyngeal/postcricoid squamous carcinogenesis, although individual postcricoid-subsite risk estimates are limited.
Show evidence (1 reference)
PMID:39219259 SUPPORT Human Clinical
"Several factors, including smoking, alcohol consumption, oncogenic genes, growth factors, Epstein-Barr virus and human papillomavirus infections can contribute to HNSCC development."
Supports tobacco and alcohol as major environmental contributors in the broader head and neck squamous cancer family that includes hypopharyngeal SCC.
Plummer-Vinson Syndrome Risk Context
Plummer-Vinson syndrome, with iron deficiency anemia, dysphagia, and upper esophageal or postcricoid webs, is a recognized premalignant context for hypopharyngeal and upper esophageal squamous cancers.
Show evidence (1 reference)
PMID:31417270 SUPPORT Human Clinical
"It is also important to recognize the association of Plummer-Vinson Syndrome with esophageal and hypopharyngeal cancer."
Supports Plummer-Vinson syndrome as a clinically relevant risk context for hypopharyngeal/postcricoid squamous carcinoma.
🔬

Clinical Trials

2
NCT04156698 PHASE_II UNKNOWN
Single-center, open-label phase 2 study of induction camrelizumab plus modified TPF chemoimmunotherapy for locally advanced hypopharyngeal carcinoma.
Show evidence (1 reference)
clinicaltrials:NCT04156698 SUPPORT Human Clinical
"This is a single-center, multidisciplinary, open-label, single-arm prospective clinical study."
Supports NCT04156698 as a directly relevant prospective phase 2 hypopharyngeal carcinoma trial.
NCT06039631 PHASE_II UNKNOWN
Trial of neoadjuvant immunotherapy plus chemotherapy followed by concurrent radiochemotherapy or organ-preserving surgery for locally advanced laryngeal and hypopharyngeal cancer.
Show evidence (1 reference)
clinicaltrials:NCT06039631 SUPPORT Human Clinical
"Against this backdrop, the current study aims to explore neoadjuvant immunotherapy combined with chemotherapy for patients with locally advanced laryngeal and hypopharyngeal cancer."
Supports the trial as relevant to locally advanced hypopharyngeal cancer.
{ }

Source YAML

click to show
name: Postcricoid Region Cancer
creation_date: "2026-05-10T20:10:37Z"
updated_date: "2026-05-10T22:20:00Z"
description: >-
  Postcricoid region cancer is a malignant neoplasm involving the postcricoid
  portion of the hypopharynx at the pharyngoesophageal junction. Most primary
  tumors in this region are managed clinically as hypopharyngeal head and neck
  cancers, commonly with squamous differentiation, and can cause dysphagia,
  voice change, airway compromise, and cervical nodal or distant metastatic
  disease.
category: Cancer
categories:
- Head and Neck Cancer
- Hypopharyngeal Cancer
- Solid Tumor
- Squamous Cell Carcinoma
synonyms:
- postcricoid carcinoma
- post-cricoid carcinoma
- postcricoid hypopharyngeal carcinoma
- postcricoid hypopharyngeal squamous cell carcinoma
disease_term:
  preferred_term: postcricoid region cancer
  term:
    id: MONDO:0004635
    label: postcricoid region cancer
parents:
- hypopharynx cancer
- head and neck cancer
prevalence:
- population: Global hypopharyngeal cancer burden
  notes: >-
    Postcricoid tumors are an uncommon anatomic subsite within hypopharyngeal
    cancer. Global epidemiology is generally reported for hypopharyngeal cancer
    as a group rather than for the postcricoid subsite alone.
  evidence:
  - reference: PMID:39286014
    reference_title: "Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from GLOBOCAN 2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypopharyngeal cancer (HC) comprises less than 5% of all malignant tumors
      in the head and neck.
    explanation: >-
      This GLOBOCAN analysis supports the rarity of hypopharyngeal cancer
      relative to other head and neck malignancies.
  - reference: PMID:39286014
    reference_title: "Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from GLOBOCAN 2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 2020, there were 84254 new HC cases globally (ASIR: 0.91 per 100000)."
    explanation: >-
      Provides a recent global incidence estimate for the broader hypopharyngeal
      cancer group that includes postcricoid tumors.
progression:
- phase: Often advanced at detection
  notes: >-
    The postcricoid subsite may remain clinically occult until dysphagia, voice
    change, airway compromise, nodal disease, or distant disease prompts
    evaluation.
  evidence:
  - reference: PMID:39286014
    reference_title: "Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from GLOBOCAN 2020."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They often present at an advanced stage, thereby resulting in high
      mortalities.
    explanation: >-
      The broader hypopharyngeal cancer epidemiology supports late presentation
      as a key clinical behavior.
  - reference: PMID:38719981
    reference_title: "Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 Gy in 35 fractions: a single-center study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hypopharyngeal squamous cell carcinoma (HSCC) is often undetected until
      advanced stages, which contributes to poor survival rates.
    explanation: >-
      This early-stage treatment cohort explicitly notes the common detection
      delay for hypopharyngeal SCC.
environmental:
- name: Tobacco and alcohol exposure
  description: >-
    Tobacco and alcohol exposure are established risk factors across head and
    neck squamous cell carcinomas and are relevant to hypopharyngeal/postcricoid
    squamous carcinogenesis, although individual postcricoid-subsite risk
    estimates are limited.
  exposure_term:
    preferred_term: exposure to tobacco smoking
    term:
      id: ECTO:6000029
      label: exposure to tobacco smoking
  evidence:
  - reference: PMID:39219259
    reference_title: Epithelial-derived head and neck squamous tumourigenesis (Review).
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Several factors, including smoking, alcohol consumption, oncogenic genes,
      growth factors, Epstein-Barr virus and human papillomavirus infections can
      contribute to HNSCC development.
    explanation: >-
      Supports tobacco and alcohol as major environmental contributors in the
      broader head and neck squamous cancer family that includes hypopharyngeal
      SCC.
- name: Plummer-Vinson Syndrome Risk Context
  description: >-
    Plummer-Vinson syndrome, with iron deficiency anemia, dysphagia, and upper
    esophageal or postcricoid webs, is a recognized premalignant context for
    hypopharyngeal and upper esophageal squamous cancers.
  evidence:
  - reference: PMID:31417270
    reference_title: "Plummer-Vinson syndrome: improving outcomes with a multidisciplinary approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is also important to recognize the association of Plummer-Vinson
      Syndrome with esophageal and hypopharyngeal cancer.
    explanation: >-
      Supports Plummer-Vinson syndrome as a clinically relevant risk context for
      hypopharyngeal/postcricoid squamous carcinoma.
pathophysiology:
- name: Malignant Transformation of Postcricoid Squamous Epithelium
  description: >-
    Squamous epithelial cells in the postcricoid hypopharynx undergo malignant
    transformation, with increased proliferation and acquisition of invasive
    behavior.
  cell_types:
  - preferred_term: squamous epithelial cell
    term:
      id: CL:0000076
      label: squamous epithelial cell
  locations:
  - preferred_term: hypopharynx
    term:
      id: UBERON:0001051
      label: hypopharynx
  biological_processes:
  - preferred_term: DNA damage response
    modifier: ABNORMAL
    term:
      id: GO:0006974
      label: DNA damage response
  - preferred_term: cell population proliferation
    modifier: INCREASED
    term:
      id: GO:0008283
      label: cell population proliferation
  downstream:
  - target: Local Invasion and Metastatic Spread
    description: >-
      Transformed squamous cells invade the hypopharyngeal wall and can spread
      to regional lymph nodes or distant sites.
  evidence:
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinoma is the most common histological type."
    explanation: >-
      Supports squamous epithelial malignant transformation as the dominant
      histologic pattern for hypopharyngeal cancers.
- name: Local Invasion and Metastatic Spread
  description: >-
    Tumor extension through the hypopharyngeal wall and spread to nodal or
    distant sites drives staging, prognosis, and multimodality treatment
    selection.
  locations:
  - preferred_term: hypopharynx
    term:
      id: UBERON:0001051
      label: hypopharynx
  biological_processes:
  - preferred_term: cell migration
    modifier: INCREASED
    term:
      id: GO:0016477
      label: cell migration
  downstream:
  - target: Dysphagia
    description: Local mass effect and impaired hypopharyngeal transit produce swallowing difficulty.
  - target: Airway and Voice Dysfunction
    description: Local extension can involve laryngeal function, vocal fold motion, and airway patency.
  - target: Adaptive Immune Resistance
    description: >-
      Progressing squamous tumors can acquire immune-evasion programs that are
      relevant to checkpoint inhibitor treatment selection.
  evidence:
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Imaging also plays a major role in its staging, including local disease
      extent, nodal and distant metastatic status, as well as to assess response
      to therapy.
    explanation: >-
      Supports local extension, nodal spread, and distant metastatic status as
      core hypopharyngeal cancer disease behaviors.
  - reference: DOI:10.3390/jpm14101048
    reference_title: Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      The review focuses on indicators, including PD-L1, CTLA-4, and tumor
      mutational burden (TMB) in predicting immunotherapy responses, highlighting
      recent developments in our understanding of the intricate interactions
      between tumor genetics and the immune milieu.
    explanation: >-
      This broader laryngeal/head-and-neck squamous cancer review supports
      checkpoint-relevant immune biology as a treatment-selection mechanism near
      the hypopharyngeal/postcricoid disease space.
- name: Adaptive Immune Resistance
  conforms_to: "immune_checkpoint_blockade#Adaptive Immune Resistance"
  description: >-
    Postcricoid and hypopharyngeal squamous tumors can be treated with PD-1
    pathway blockade in chemoimmunotherapy protocols, reflecting checkpoint-
    mediated suppression of antitumor T-cell activity rather than direct targeting
    of invasion alone.
  biological_processes:
  - preferred_term: negative regulation of T cell mediated immunity
    modifier: INCREASED
    term:
      id: GO:0002710
      label: negative regulation of T cell mediated immunity
  downstream:
  - target: T Cell Exhaustion and Immune Escape
    description: >-
      Persistent checkpoint engagement suppresses cytotoxic T-cell function and
      supports tumor immune escape.
  evidence:
  - reference: PMID:38762484
    reference_title: "PD-1/PD-L1 axis in cancer: Regulatory mechanisms and therapeutic targets."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in
      cancer development and progression.
    explanation: >-
      Supports PD-1/PD-L1 axis exploitation as an adaptive immune resistance
      mechanism across cancers.
  - reference: DOI:10.3390/jpm14101048
    reference_title: Personalized Treatment Strategies via Integration of Gene Expression Biomarkers in Molecular Profiling of Laryngeal Cancer
    supports: PARTIAL
    evidence_source: OTHER
    snippet: >-
      The review focuses on indicators, including PD-L1, CTLA-4, and tumor
      mutational burden (TMB) in predicting immunotherapy responses, highlighting
      recent developments in our understanding of the intricate interactions
      between tumor genetics and the immune milieu.
    explanation: >-
      Supports checkpoint-relevant immune biomarkers in an adjacent head-and-neck
      squamous cancer setting; applied conservatively because it is not
      postcricoid-subsite specific.
- name: T Cell Exhaustion and Immune Escape
  conforms_to: "immune_checkpoint_blockade#T Cell Exhaustion and Immune Escape"
  description: >-
    Suppressed tumor-infiltrating T cells can lose effective cytokine production
    and cytolytic activity, allowing immune escape within the tumor
    microenvironment.
  cell_types:
  - preferred_term: exhausted T cell
    term:
      id: CL:0011025
      label: exhausted T cell
  biological_processes:
  - preferred_term: exhausted T cell differentiation
    modifier: INCREASED
    term:
      id: GO:0160083
      label: exhausted T cell differentiation
  evidence:
  - reference: PMID:26086965
    reference_title: T-cell exhaustion in the tumor microenvironment.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The exhausted T cells in the tumor microenvironment show overexpressed
      inhibitory receptors, decreased effector cytokine production and cytolytic
      activity, leading to the failure of cancer elimination.
    explanation: >-
      Supports exhausted T-cell immune escape as a downstream checkpoint-related
      tumor microenvironment state.
histopathology:
- name: Squamous Cell Carcinoma
  finding_term:
    preferred_term: Squamous Cell Carcinoma
    term:
      id: NCIT:C2929
      label: Squamous Cell Carcinoma
  frequency: VERY_FREQUENT
  diagnostic: true
  description: >-
    Squamous cell carcinoma is the dominant histologic type for hypopharyngeal
    cancers and is the expected histology for most postcricoid primary tumors.
  evidence:
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinoma is the most common histological type."
    explanation: >-
      Directly supports squamous carcinoma as the common histology in
      hypopharyngeal cancer.
phenotypes:
- category: Head and Neck
  name: Dysphagia
  frequency: FREQUENT
  diagnostic: true
  description: >-
    Difficulty swallowing is a common presenting symptom because the tumor
    occupies the postcricoid hypopharynx near the pharyngoesophageal junction.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:38711727
    reference_title: "Clinical Conundrum: Unveiling a Unique Presentation of Hypopharyngeal Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 33-year-old female presented at a tertiary care hospital in Western
      India with hoarseness of voice, difficulty in swallowing, productive
      cough, and neck pain for two months with an abrupt increase in the
      severity of all symptoms in two days.
    explanation: >-
      This post-cricoid growth case directly supports dysphagia as a presenting
      manifestation.
- category: Head and Neck
  name: Hoarse Voice
  frequency: FREQUENT
  description: >-
    Hoarseness can reflect local tumor extension, vocal cord paresis, or
    associated laryngeal involvement.
  phenotype_term:
    preferred_term: Hoarse voice
    term:
      id: HP:0001609
      label: Hoarse voice
  evidence:
  - reference: PMID:19078805
    reference_title: Postcricoid pharyngeal carcinoma mimicking bulbar amyotrophic lateral sclerosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This report describes a 73-year-old man who had a 10-month history of
      progressive hoarseness, dysphagia, and respiratory failure.
    explanation: >-
      This postcricoid carcinoma case supports hoarseness and swallowing
      symptoms as presenting features.
- category: Respiratory
  name: Respiratory Failure or Airway Compromise
  frequency: OCCASIONAL
  description: >-
    Advanced local disease can compromise the airway directly or through vocal
    cord paralysis.
  phenotype_term:
    preferred_term: Respiratory insufficiency
    term:
      id: HP:0002093
      label: Respiratory insufficiency
  evidence:
  - reference: PMID:19078805
    reference_title: Postcricoid pharyngeal carcinoma mimicking bulbar amyotrophic lateral sclerosis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Computed tomography of his neck identified a postcricoid squamous cell
      carcinoma, which was causing bilateral vocal cord paralysis.
    explanation: >-
      Supports airway and vocal cord involvement as a severe manifestation of
      postcricoid carcinoma.
- category: Constitutional
  name: Anemia in Plummer-Vinson Syndrome Risk Context
  frequency: OCCASIONAL
  description: >-
    Iron deficiency anemia is not a tumor manifestation by itself, but it is a
    key feature of Plummer-Vinson syndrome, a premalignant context for
    hypopharyngeal and upper esophageal squamous carcinoma.
  phenotype_term:
    preferred_term: Anemia
    term:
      id: HP:0001903
      label: Anemia
  evidence:
  - reference: PMID:31417270
    reference_title: "Plummer-Vinson syndrome: improving outcomes with a multidisciplinary approach."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Plummer-Vinson syndrome is a rare condition associated with dysphagia,
      iron deficiency, and esophageal webs.
    explanation: >-
      Supports anemia/iron deficiency as part of the postcricoid-relevant
      Plummer-Vinson risk context.
genetic:
- name: Somatic head and neck squamous carcinoma alterations
  relationship_type: SUSCEPTIBILITY
  notes: >-
    Postcricoid-specific molecular series are limited. Broader head and neck
    squamous carcinoma literature supports recurrent somatic alterations and
    pathway disruption involving tumor suppressor, growth factor, and immune
    evasion programs.
  evidence:
  - reference: PMID:39219259
    reference_title: Epithelial-derived head and neck squamous tumourigenesis (Review).
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Comprehensive genomic, transcriptomic, metabolomic, microbiome and
      proteomic analyses allow researchers to identify important biological
      markers such as genetic alterations, gene expression signatures and
      protein markers that drive HNSCC tumours.
    explanation: >-
      Supports molecular alteration as relevant in the broader HNSCC family;
      the assertion is deliberately broad because the cited evidence is not
      postcricoid-subsite specific.
- name: TP53 alteration in head and neck squamous carcinoma
  gene_term:
    preferred_term: TP53
    term:
      id: hgnc:11998
      label: TP53
  relationship_type: SUSCEPTIBILITY
  notes: >-
    TP53 alteration is a major somatic feature of smoking-related and
    HPV-negative head and neck squamous cell carcinoma. This is included as
    broader HNSCC context rather than as a postcricoid-subsite-specific
    molecular frequency.
  evidence:
  - reference: PMID:25631445
    reference_title: Comprehensive genomic characterization of head and neck squamous cell carcinomas.
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Smoking-related HNSCCs demonstrate near universal loss-of-function TP53
      mutations and CDKN2A inactivation with frequent copy number alterations
      including amplification of 3q26/28 and 11q13/22.
    explanation: >-
      Supports TP53 as a major altered gene in broader HNSCC; marked PARTIAL
      because the TCGA cohort is not specific to the postcricoid subsite.
diagnosis:
- name: Endoscopic Examination and Biopsy
  description: >-
    Endoscopy is used for direct mucosal evaluation, staging, and biopsy
    confirmation of suspected postcricoid or hypopharyngeal lesions.
  diagnosis_term:
    preferred_term: diagnostic procedure
    term:
      id: MAXO:0000003
      label: diagnostic procedure
  evidence:
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical examination and endoscopy play an integral role in its detection
      and staging.
    explanation: >-
      Supports endoscopy as a core diagnostic and staging procedure for
      hypopharyngeal cancer.
  - reference: PMID:38711727
    reference_title: "Clinical Conundrum: Unveiling a Unique Presentation of Hypopharyngeal Carcinoma."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Squamous cell carcinoma was confirmed on the biopsy report."
    explanation: >-
      Supports biopsy confirmation in a case with post-cricoid growth.
- name: Imaging for Local, Nodal, and Distant Staging
  description: >-
    Cross-sectional imaging defines local extent, nodal involvement, distant
    metastatic status, treatment response, and recurrence versus post-treatment
    change.
  diagnosis_term:
    preferred_term: computed tomography
    term:
      id: NCIT:C17204
      label: Computed Tomography
  evidence:
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Imaging also plays a major role in its staging, including local disease
      extent, nodal and distant metastatic status, as well as to assess response
      to therapy.
    explanation: >-
      Supports imaging for staging and treatment-response assessment in
      hypopharyngeal cancer.
treatments:
- name: Radical Radiotherapy for Early-Stage Hypopharyngeal SCC
  description: >-
    Organ-preserving radiotherapy is an evidence-supported option for selected
    early-stage hypopharyngeal SCC, including small postcricoid-region subsets.
  treatment_term:
    preferred_term: radiation therapy
    term:
      id: MAXO:0000014
      label: radiation therapy
  target_mechanisms:
  - target: Malignant Transformation of Postcricoid Squamous Epithelium
    treatment_effect: INHIBITS
    description: >-
      Definitive radiotherapy targets proliferating malignant squamous tumor
      cells at the primary site.
  evidence:
  - reference: PMID:38719981
    reference_title: "Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 Gy in 35 fractions: a single-center study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This study supports radical radiotherapy as an effective approach for
      optimal tumor control in patients with early stage HSCC.
    explanation: >-
      Supports radical radiotherapy as an organ-preserving option for
      early-stage hypopharyngeal SCC.
- name: Surgery-Based Therapy for Resectable Hypopharyngeal Carcinoma
  description: >-
    Surgery-based therapy, often followed by adjuvant radiotherapy with or
    without chemotherapy depending on stage and risk features, is used for
    resectable hypopharyngeal/postcricoid disease.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
  target_mechanisms:
  - target: Local Invasion and Metastatic Spread
    treatment_effect: INHIBITS
    description: >-
      Resection removes locally invasive tumor, with adjuvant therapy selected
      for residual local, nodal, or metastatic risk.
  evidence:
  - reference: PMID:36937435
    reference_title: Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SBT can obtain significant survival benefits when compared with definitive
      CRT for the whole cohort of patients.
    explanation: >-
      Supports surgery-based therapy as an important treatment modality for
      hypopharyngeal carcinoma.
  - reference: DOI:10.1055/s-0042-1759504
    reference_title: "Imaging Recommendations for Diagnosis, Staging and Management of Larynx and Hypopharynx Cancer"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Advanced disease is treated with multimodality of either chemoradiotherapy
      or surgery followed by adjuvant radiotherapy with or without concurrent
      chemotherapy.
    explanation: >-
      Supports multimodality treatment for advanced hypopharyngeal cancer.
- name: Induction Chemoimmunotherapy for Locally Advanced Hypopharyngeal SCC
  description: >-
    Phase II data support induction camrelizumab plus modified TPF as an
    emerging organ-preservation strategy for locally advanced hypopharyngeal
    squamous cell carcinoma, with surgery and adjuvant treatment reserved for
    non-responders in the studied protocol.
  treatment_term:
    preferred_term: pharmacotherapy
    term:
      id: MAXO:0000058
      label: pharmacotherapy
    therapeutic_agent:
    - preferred_term: camrelizumab
    - preferred_term: docetaxel
    - preferred_term: cisplatin
      term:
        id: CHEBI:27899
        label: cisplatin
    - preferred_term: capecitabine
      term:
        id: CHEBI:31348
        label: capecitabine
  target_mechanisms:
  - target: Adaptive Immune Resistance
    treatment_effect: INHIBITS
    description: >-
      Camrelizumab-containing induction therapy includes PD-1 pathway blockade,
      linking this regimen to checkpoint-mediated immune escape rather than to
      local invasion alone.
  - target: Local Invasion and Metastatic Spread
    treatment_effect: MODULATES
    description: >-
      The combined chemotherapy and immunotherapy regimen aims to shrink locally
      advanced tumor and select patients for organ-preserving therapy versus
      surgery.
  evidence:
  - reference: PMID:38898018
    reference_title: "Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This phase II trial aimed to determine the efficacy and safety of
      induction chemoimmunotherapy of camrelizumab plus modified TPF in locally
      advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698).
    explanation: >-
      Supports chemoimmunotherapy as an emerging treatment strategy for locally
      advanced hypopharyngeal SCC.
  - reference: PMID:38898018
    reference_title: "Camrelizumab-based induction chemoimmunotherapy in locally advanced stage hypopharyngeal carcinoma: phase II clinical trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      After induction therapy, the ORR was 82.4% (42/51), meeting the
      prespecified endpoint.
    explanation: >-
      Provides trial outcome evidence for response after induction
      chemoimmunotherapy.
clinical_trials:
- name: NCT04156698
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Single-center, open-label phase 2 study of induction camrelizumab plus
    modified TPF chemoimmunotherapy for locally advanced hypopharyngeal
    carcinoma.
  evidence:
  - reference: clinicaltrials:NCT04156698
    reference_title: A Phase II, Single-center, Open-label, Single-arm Study of Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This is a single-center, multidisciplinary, open-label, single-arm
      prospective clinical study.
    explanation: >-
      Supports NCT04156698 as a directly relevant prospective phase 2
      hypopharyngeal carcinoma trial.
- name: NCT06039631
  phase: PHASE_II
  status: UNKNOWN
  description: >-
    Trial of neoadjuvant immunotherapy plus chemotherapy followed by concurrent
    radiochemotherapy or organ-preserving surgery for locally advanced
    laryngeal and hypopharyngeal cancer.
  evidence:
  - reference: clinicaltrials:NCT06039631
    reference_title: Neoadjuvant Immunotherapy And Chemotherapy Followed By Concurrent Chemoradiation Or Organ Preservation Surgery In Locally Advanced Laryngeal Cancer And Hypopharyngeal Cancer
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Against this backdrop, the current study aims to explore neoadjuvant
      immunotherapy combined with chemotherapy for patients with locally
      advanced laryngeal and hypopharyngeal cancer.
    explanation: >-
      Supports the trial as relevant to locally advanced hypopharyngeal cancer.
datasets: []
notes: >-
  The initial page was created before Falcon deep research, then expanded using
  the Falcon report and fetched reference caches. Mechanistic and molecular
  assertions are conservative when the available evidence is for hypopharyngeal
  cancer or broader head and neck squamous cell carcinoma rather than the
  postcricoid subsite alone. Review follow-up added checkpoint-linked immune
  evasion and TP53 context from broader head-and-neck squamous carcinoma
  literature. Additional symptoms listed in the Falcon report, including
  odynophagia, stridor, and otalgia, were not expanded here because the available
  cached DOI abstract does not include directly quotable symptom text and the
  suggested stridor HPO identifier resolves locally to an unrelated term.
📚

References & Deep Research

Deep Research

1
Falcon
Postcricoid Region Cancer (Postcricoid Hypopharyngeal Carcinoma): Disease Characteristics Research Report
Edison Scientific Literature 37 citations 2026-05-10T16:32:10.299240

Postcricoid Region Cancer (Postcricoid Hypopharyngeal Carcinoma): Disease Characteristics Research Report

Target disease

Disease name: Postcricoid region cancer (most commonly postcricoid hypopharyngeal squamous cell carcinoma, a hypopharyngeal cancer subsite) (glastonbury2020headandneck pages 1-2, mousavi2024globalepidemiologyand pages 1-2).


Executive summary (current understanding)

Postcricoid region cancer is best conceptualized as a hypopharyngeal malignancy arising from the postcricoid region (anterior wall of the hypopharynx, overlying the posterior cricoid cartilage), most often squamous cell carcinoma (SCC). It is clinically important because (i) it is frequently advanced at diagnosis, (ii) it exhibits submucosal spread toward the cervical esophagus, and (iii) treatment requires balancing oncologic control with laryngo-esophageal function preservation (glastonbury2020headandneck pages 1-2, sahu2023imagingrecommendationsfor pages 5-8, katano2024earlystagehypopharyngealsquamous pages 1-2).

A concise evidence table of key recent quantitative findings is provided below.

Topic Key quantitative data Key qualitative takeaway Source (first author, year) URL
Global epidemiology of hypopharyngeal cancer (includes postcricoid subsite) 84,254 new cases globally in 2020; ASIR 0.91/100,000; 38,599 deaths; ASMR 0.41/100,000; MIR 0.45; projected increase by 2040: new cases +50%, deaths +55%; subsite distribution: ~70% pyriform sinus, ~25% posterior pharyngeal wall, remainder largely post-cricoid; HC is <5% of head and neck malignancies (mousavi2024globalepidemiologyand pages 1-2, mousavi2024globalepidemiologyand pages 2-3) Postcricoid-region cancer is best understood as a rare hypopharyngeal cancer subsite within a high-mortality disease that is more common in men and often diagnosed late. Mousavi, 2024 https://doi.org/10.3389/fonc.2024.1398063
Symptoms and NCCN diagnostic workup Common symptoms: hoarseness, breathing difficulty, dysphagia/odynophagia, foreign-body sensation, ear ache; advanced signs include stridor/aspiration. NCCN-referenced workup: examination under anesthesia with endoscopy/biopsy; CECT and/or MRI of primary and neck; chest CT for advanced nodal disease/smokers; FDG PET-CT for stage III-IV disease (sahu2023imagingrecommendationsfor pages 1-2, sahu2023imagingrecommendationsfor pages 5-8, sahu2023imagingrecommendationsfor pages 2-3) Endoscopy is essential for mucosal assessment and biopsy, but CT/MRI/PET are required to define submucosal spread, cartilage invasion, nodal disease, response, and recurrence in postcricoid tumors. Sahu, 2023 https://doi.org/10.1055/s-0042-1759504
Radical radiotherapy outcomes for early-stage HSCC, including postcricoid subsite Uniform RT: 70 Gy in 35 fractions to primary site plus elective nodal irradiation; 5-year OS 80.7% (95% CI 66.5-89.4%); 5-year DFS 66.4%; 5-year LRC 79.3%; postcricoid subsite 5-year OS 100% in this small series; no grade >=3 toxicities reported (katano2024earlystagehypopharyngealsquamous pages 1-2, katano2024earlystagehypopharyngealsquamous pages 2-5) For stage I-II hypopharyngeal SCC, organ-preserving radical RT can produce strong long-term control with favorable toxicity; postcricoid outcomes were encouraging but based on very small numbers. Katano, 2024 https://doi.org/10.1007/s00405-024-08722-w
Surgery-based therapy vs definitive chemoradiotherapy in hypopharyngeal carcinoma 167 patients; 5-year OS 59.7% with surgery-based therapy vs 24.0% with definitive CRT (p<0.0001); 5-year PFS 49.9% vs 22.6% (p=0.0002); surgery also improved LFFS, RFFS, DMFFS; survival similar between modalities mainly for T3 or stage III disease (lin2023survivalanalysesof pages 1-2, lin2023survivalanalysesof pages 2-3) In retrospective data, surgery-based therapy often outperformed definitive CRT overall, but organ-preservation approaches may remain reasonable for selected T3/stage III cases. Extensive postcricoid/esophageal inlet involvement favored total laryngectomy/pharyngectomy. Lin, 2023 https://doi.org/10.3389/fonc.2023.1109417
Plummer-Vinson syndrome (PVS) as a risk context for postcricoid/pharyngeal SCC Reported malignancy incidence in PVS: 3-15% overall; one report cites post-cricoid carcinoma in ~4-16% across studies; yearly surveillance endoscopy is commonly suggested though no definitive guideline exists (patil2023endoscopicsubmucosaldissection pages 1-2, lo2019plummervinsonsyndromeimproving pages 5-6, patil2023endoscopicsubmucosaldissection pages 2-4, lo2019plummervinsonsyndromeimproving pages 2-3) PVS (iron deficiency anemia + dysphagia + upper esophageal/post-cricoid web) is a classic premalignant association for postcricoid/pharyngeal SCC; long-term surveillance is generally recommended despite limited evidence and lack of standardized intervals. Lo, 2019; Patil, 2023 https://doi.org/10.2147/JMDH.S180410 ; https://doi.org/10.1055/s-0042-1759510
Organ-preservation chemoimmunotherapy studies/trials NCT04156698: phase II, n=51, camrelizumab + modified TPF; ORR 82.4% (42/51); 2-year OS 83.0%; 2-year PFS 77.1%; 2-year larynx preservation rate 70.0%. NCT06039631: randomized phase II, planned n=82; neoadjuvant chemoimmunotherapy followed by organ-preservation surgery vs concurrent chemoradiation; RT arm 70 Gy/35 fractions + weekly cisplatin; primary endpoint 2-year PFS; key secondary endpoints include larynx preservation, OS, QoL (NCT04156698 chunk 1, NCT06039631 chunk 1) Recent organ-preservation strategies are shifting toward PD-1-based chemoimmunotherapy for locally advanced hypopharyngeal/laryngeal cancer, aiming to improve response and preserve laryngeal function without routine upfront total laryngectomy. Gong/Wang, 2024-2023 (NCT04156698/NCT06039631) https://clinicaltrials.gov/study/NCT04156698 ; https://clinicaltrials.gov/study/NCT06039631

Table: This table summarizes key recent evidence and quantitative findings relevant to postcricoid-region cancer within hypopharyngeal squamous cell carcinoma. It highlights epidemiology, diagnosis, outcomes, risk context, and emerging organ-preservation approaches.


1. Disease information

1.1 Disease overview and definition

  • Definition/anatomic subsite: The postcricoid region is described as the anterior wall of the hypopharynx and corresponds to mucosa overlying the posterior surface of the cricoid cartilage (glastonbury2020headandneck pages 1-2). Postcricoid region cancer is therefore a subtype of hypopharyngeal cancer arising from this subsite (glastonbury2020headandneck pages 1-2, mousavi2024globalepidemiologyand pages 1-2).

1.2 Key identifiers and ontology mappings

  • ICD-O-3 topography (commonly used in SEER/registry datasets): C13.0 = postcricoid region ().
  • MONDO: OpenTargets returns MONDO_0021358 (neoplasm of hypopharynx) as a related disease entity in its hypopharynx cancer space (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma). A postcricoid-specific MONDO term was not retrieved in the current evidence set.
  • EFO terms observed via OpenTargets context: hypopharyngeal carcinoma EFO_0002938; hypopharyngeal squamous cell carcinoma EFO_1001960 (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma).

1.3 Common synonyms

  • Postcricoid hypopharyngeal carcinoma; post-cricoid carcinoma; hypopharyngeal SCC of the postcricoid region; postcricoid-region hypopharyngeal cancer (li2026novellaryngealpreservation pages 1-2, glastonbury2020headandneck pages 1-2).

1.4 Evidence source type

The evidence here is largely from aggregated disease-level resources (GLOBOCAN 2020 analysis, imaging recommendations, trials) and cohort studies/case series, not single EHR-derived patient observations (mousavi2024globalepidemiologyand pages 1-2, sahu2023imagingrecommendationsfor pages 1-2, katano2024earlystagehypopharyngealsquamous pages 1-2).


2. Etiology

2.1 Causal factors and mechanisms (high-level)

Most postcricoid cancers are mucosal epithelial SCCs arising in the upper aerodigestive tract, consistent with the broader hypopharyngeal SCC pathogenesis (mousavi2024globalepidemiologyand pages 1-2, li2026novellaryngealpreservation pages 1-2).

2.2 Risk factors

Lifestyle/environmental: * Tobacco and alcohol are highlighted as major risk factors in imaging-based clinical guidance for larynx/hypopharynx cancers (sahu2023imagingrecommendationsfor pages 1-2).

Syndromic/premalignant association (important for the postcricoid region): Plummer–Vinson syndrome (PVS) * PVS is classically defined by the triad of iron deficiency anemia, post-cricoid dysphagia, and an upper esophageal/post-cricoid web, and is consistently described as associated with upper aerodigestive squamous cancers (patil2023endoscopicsubmucosaldissection pages 1-2, lo2019plummervinsonsyndromeimproving pages 1-2). * Quantitative risk ranges reported in retrieved sources: * “Malignancies occur at an incidence of 3–15%” in PVS (lo2019plummervinsonsyndromeimproving pages 2-3). * A pooled frequency range reported in one PVS-focused source indicates post-cricoid carcinoma occurs in ~4–16% across studies (patil2023endoscopicsubmucosaldissection pages 1-2).

Protective factors: not clearly identified in the retrieved evidence set for this specific subsite.

2.3 Gene–environment considerations

The strongest evidence in this set supports classic carcinogen exposure (tobacco/alcohol) and mucosal vulnerability due to iron deficiency (PVS) as converging pathways toward squamous carcinogenesis (sahu2023imagingrecommendationsfor pages 1-2, patil2023endoscopicsubmucosaldissection pages 2-4).


3. Phenotypes (clinical presentation)

3.1 Key symptoms and signs

Common presenting features for larynx/hypopharynx cancers include hoarseness, breathing difficulty, dysphagia/odynophagia, foreign-body sensation, ear ache, and advanced presentations including stridor or aspiration (sahu2023imagingrecommendationsfor pages 1-2).

Early-stage hypopharyngeal SCC (including postcricoid) is often not detected promptly. One 2024 cohort reports: “HSCC is often undetected until advanced stages” and notes that “More than 50% of patients with hypopharyngeal cancers … present at an advanced stage.” (katano2024earlystagehypopharyngealsquamous pages 1-2).

3.2 Phenotype characteristics

  • Typical onset: adult-onset cancer (registry-level; not a congenital disease entity).
  • Progression: often insidious until advanced.

3.3 Quality-of-life impact

Swallowing and voice/airway issues are intrinsic to hypopharyngeal/postcricoid tumors due to proximity to the larynx and esophageal inlet; contemporary organ-preservation trials explicitly include QoL instruments (e.g., EORTC QLQ-H&N35; MDADI; VHI-10) as endpoints (NCT06957938 chunk 2, NCT06039631 chunk 1).

3.4 Suggested HPO terms (examples)

  • Dysphagia HP:0002015
  • Odynophagia HP:0033050
  • Hoarseness/dysphonia HP:0001609
  • Stridor HP:0010448
  • Aspiration HP:0002835
  • Otalgia (ear pain) HP:0030766

(These are suggested mappings based on the symptom set described in the clinical literature above; the exact HPO identifiers were not explicitly provided in retrieved sources.)


4. Genetic / molecular information

4.1 Somatic landscape (current understanding; largely extrapolated from HNSCC/HSCC)

Postcricoid cancers are usually SCC and share canonical head-and-neck SCC alterations.

  • A 2024 review emphasizes TP53 as central: “Mutation on the TP53 tumour suppressor gene is a key factor in cancer development” and notes TP53-related biology intersects with tumor immune behavior including PD-L1 (CD274) in some contexts (shirima2024epithelial‑derivedheadand pages 3-4).
  • A 2023 review lists recurrently altered tumor suppressors and oncogenes in HNSCC, including TP53, CDKN2A, NOTCH1, FAT1, EGFR, PIK3CA, and RAS/HRAS (afshari2023potentialalternativetherapeutic pages 1-2).
  • OpenTargets associations (supportive, not definitive for this subsite) link hypopharyngeal carcinoma space to targets including ADH1B (with PubMed-listed evidence) and, in related pharyngeal SCC entities, to TP53, EGFR, MET, PIK3CA, NOTCH1, KMT2D/KMT2C, etc. (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma).

4.2 Key pathways/processes implicated

From the retrieved HNSCC-focused reviews, major implicated signaling and cellular processes include: * Cell-cycle dysregulation / DNA damage response (TP53, CDKN2A/p16, RB1/CCND1 context) (shirima2024epithelial‑derivedheadand pages 3-4, afshari2023potentialalternativetherapeutic pages 1-2). * RTK/RAS and EGFR signaling (EGFR and RAS family contributions, therapeutic implications such as cetuximab resistance) (shirima2024epithelial‑derivedheadand pages 3-4). * PI3K/AKT/mTOR pathway and PTEN (shirima2024epithelial‑derivedheadand pages 3-4). * Squamous differentiation programs including NOTCH signaling (afshari2023potentialalternativetherapeutic pages 1-2). * Immune evasion/checkpoint biology (PD-1/PD-L1 axis relevance in SCC immunotherapy selection) (shirima2024epithelial‑derivedheadand pages 3-4).

4.3 Suggested GO terms (examples)

  • GO:0007049 cell cycle
  • GO:0006974 cellular response to DNA damage stimulus
  • GO:0008285 negative regulation of cell proliferation
  • GO:0008283 cell population proliferation
  • GO:0045123 cellular extravasation / invasion (as a proxy for local invasion; general)
  • GO:0006955 immune response; GO:0045087 innate immune response

(These are suggested mechanism mappings; explicit GO annotations were not provided in the retrieved sources.)

4.4 Suggested Cell Ontology terms (examples)

  • CL:0000066 epithelial cell (tumor origin)
  • CL:0000624 CD8-positive, alpha-beta T cell (immune microenvironment)
  • CL:0000235 macrophage (TME)

(Again, suggested mappings; CL identifiers are not explicitly stated in retrieved sources.)


5. Environmental information

5.1 Environmental/lifestyle factors

  • Tobacco and alcohol exposure are repeatedly emphasized as major risk factors for hypopharyngeal/laryngeal cancers (sahu2023imagingrecommendationsfor pages 1-2).

5.2 Infectious agents

HPV appears to be relevant to a subset of non-oropharyngeal SCCs, but postcricoid-specific HPV prevalence was not extracted from the current evidence set.


6. Mechanism / pathophysiology

6.1 Causal chain (subsite-relevant, evidence-based narrative)

  1. Chronic exposures/host susceptibility (tobacco/alcohol carcinogens; iron deficiency and mucosal degeneration in PVS) predispose to squamous mucosal dysplasia and malignant transformation (sahu2023imagingrecommendationsfor pages 1-2, patil2023endoscopicsubmucosaldissection pages 2-4).
  2. Tumor arises in a region with propensity for submucosal spread; imaging guidance notes postcricoid hypopharyngeal carcinoma can show submucosal spread toward the cervical esophagus, and MRI can better delineate extent (sahu2023imagingrecommendationsfor pages 5-8).
  3. Progressive local growth leads to dysphagia and airway/voice symptoms, while deep spread and nodal metastasis drive advanced-stage presentation (sahu2023imagingrecommendationsfor pages 1-2, katano2024earlystagehypopharyngealsquamous pages 1-2).

6.2 Immune system involvement (current understanding)

The broader HNSCC literature emphasizes immune checkpoint biology (PD-1/PD-L1) as both a therapeutic target and part of immune evasion programs. TP53 alterations may intersect with immune-related tumor behaviors, and immune checkpoint inhibition is central in contemporary organ-preservation trials for hypopharyngeal cancer (shirima2024epithelial‑derivedheadand pages 3-4, NCT04156698 chunk 1).


7. Anatomical structures affected

7.1 Organ/tissue localization

  • Primary site: postcricoid region of the hypopharynx (anterior wall hypopharynx; mucosa over posterior cricoid cartilage) (glastonbury2020headandneck pages 1-2).

7.2 Suggested UBERON terms (examples)

  • Hypopharynx: UBERON:0001727 (suggested)
  • Cricoid cartilage: UBERON:0002379 (suggested)

(UBERON IDs are provided as suggested ontology mappings; explicit UBERON annotations were not contained in the retrieved text.)

7.3 Visual evidence for anatomy and subsite imaging

The Sahu 2023 imaging recommendations include CT figures of normal hypopharynx anatomy and imaging of postcricoid-region cancer, as well as TNM staging tables, supporting subsite localization and staging criteria (sahu2023imagingrecommendationsfor media 624946c3, sahu2023imagingrecommendationsfor media dd0e55cc, sahu2023imagingrecommendationsfor media 9d694104, sahu2023imagingrecommendationsfor media 0adf3cdb, sahu2023imagingrecommendationsfor media ea5671f7, sahu2023imagingrecommendationsfor media 2fc9a3ce).


8. Temporal development

8.1 Onset and progression

Hypopharyngeal SCC commonly presents late; early disease may be subtle. In the 2024 early-stage HSCC radiotherapy cohort: “HSCC is often undetected until advanced stages” and “More than 50% of patients … present at an advanced stage” (katano2024earlystagehypopharyngealsquamous pages 1-2).

8.2 Staging system

Staging follows AJCC TNM for hypopharyngeal SCC, with T descriptors incorporating extension/subsite involvement and invasion of structures including the cricoid cartilage (T4a) (sahu2023imagingrecommendationsfor pages 10-12).


9. Inheritance and population

9.1 Epidemiology (prioritizing 2024)

A 2024 GLOBOCAN 2020 analysis reported: * 84,254 new cases globally in 2020; ASIR 0.91 per 100,000. * 38,599 deaths in 2020; ASMR 0.41 per 100,000. * MIR 0.45. * Projected increases by 2040: +50% new cases and +55% deaths (mousavi2024globalepidemiologyand pages 1-2).

Subsite distribution of hypopharyngeal cancer reported in the same source: ~70% pyriform sinus, ~25% posterior pharyngeal wall, remainder largely post-cricoid (mousavi2024globalepidemiologyand pages 1-2).

9.2 Sex and age distribution

Hypopharyngeal cancer shows higher incidence/mortality in men than women and increases with age (notably ≥70 years) (mousavi2024globalepidemiologyand pages 1-2, mousavi2024globalepidemiologyand pages 2-3).


10. Diagnostics

10.1 Clinical tests and imaging (guideline-style synthesis)

Imaging recommendations emphasize that endoscopy is essential for mucosal assessment but is insufficient for complete staging because submucosal and deep-space spread can be missed.

NCCN-referenced diagnostic workup items (as quoted/compiled in Sahu 2023): * “examination under anesthesia with endoscopy” * “CECT and/ or MRI for primary and neck” * “Chest CT … for advanced nodal disease” * “FDG PET-CT … for stage III-IV disease” (sahu2023imagingrecommendationsfor pages 1-2)

Postcricoid-specific imaging note: post-cricoid hypopharyngeal carcinoma is described as uncommon and “often shows submucosal spread toward the cervical esophagus,” with MRI better delineating extent (sahu2023imagingrecommendationsfor pages 5-8).

10.2 Histopathology

Squamous cell carcinoma is the predominant histology in hypopharyngeal cancer (mousavi2024globalepidemiologyand pages 1-2, li2026novellaryngealpreservation pages 1-2).

10.3 Biomarkers (current practice direction)

PD-1/PD-L1 axis is clinically actionable in HNSCC broadly and is integral to the modern immunotherapy-based organ-preservation strategies tested in hypopharyngeal cancer trials (NCT04156698 chunk 1, NCT06039631 chunk 1).

10.4 Differential diagnosis

Sahu 2023 notes non-squamous malignant lesions are rare and often submucosal; a full differential diagnosis list was not extracted in the current evidence set (sahu2023imagingrecommendationsfor pages 1-2).


11. Outcome / prognosis

11.1 Survival statistics from recent/authoritative studies

  • Early-stage hypopharyngeal SCC treated with definitive RT (70 Gy/35 fractions) reported 5-year OS 80.7%, and for the postcricoid subsite 5-year OS 100% in a small subsite-stratified subset (katano2024earlystagehypopharyngealsquamous pages 1-2).
  • For hypopharyngeal carcinoma treatment modality comparisons (retrospective): 5-year OS 59.7% (surgery-based therapy) vs 24.0% (definitive chemoradiotherapy) (p<0.0001), and 5-year PFS 49.9% vs 22.6% (p=0.0002) (lin2023survivalanalysesof pages 1-2).

11.2 Prognostic factors

Performance status (ECOG PS) was an independent OS risk factor in the early-stage RT cohort (HR 8.457) (katano2024earlystagehypopharyngealsquamous pages 1-2).


12. Treatment

12.1 Standard modalities (real-world implementation)

Early stage: single-modality RT or surgery; a uniform definitive RT approach of 70 Gy/35 fractions with elective nodal irradiation is feasible with low high-grade toxicity in one modern series (katano2024earlystagehypopharyngealsquamous pages 1-2).

Advanced disease: multimodality management. Imaging recommendations summarize: “Early stage disease is treated with single modalities such as radiotherapy or surgery. Advanced disease is treated with multimodality of either chemoradiotherapy or surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy.” (sahu2023imagingrecommendationsfor pages 1-2).

12.2 Surgery vs definitive CRT

A retrospective cohort comparing surgery-based therapy (SBT) vs definitive chemoradiotherapy (CRT) found significantly better survival with SBT overall; however, for some subgroups (e.g., T3/stage III) survival differences were less pronounced (lin2023survivalanalysesof pages 1-2).

12.3 Immunotherapy and organ-preservation developments (prioritizing 2023–2024)

Key 2024 phase II trial (directly in hypopharyngeal SCC): * Nature Communications 2024 reports: “This phase II trial aimed to determine the efficacy and safety of induction chemoimmunotherapy of camrelizumab plus modified TPF in locally advanced hypopharyngeal squamous cell carcinoma (LA HSCC) (NCT04156698).” It reports ORR 82.4% and interim 2-year OS/PFS/LPR outcomes: 2-year OS 83.0%, PFS 77.1%, larynx preservation rate 70.0% (sahu2023imagingrecommendationsfor media ea5671f7, NCT04156698 chunk 1).

Ongoing 2023-start randomized phase II organ-preservation strategy (larynx/hypopharynx): * NCT06039631 (Fudan University; recruiting; start Aug 22, 2023) randomizes post-neoadjuvant chemoimmunotherapy patients to organ-preservation surgery vs concurrent chemoradiation (RT 70 Gy/35 fractions plus weekly cisplatin in one arm), with adjuvant toripalimab; primary endpoint is 2-year PFS and key secondary endpoints include larynx preservation rate and QoL (MDADI, VHI-10) (NCT06039631 chunk 1).

12.4 Suggested MAXO terms (examples)

  • Radiotherapy MAXO:0000016 (suggested)
  • Chemotherapy MAXO:0000058 (suggested)
  • Surgery / surgical excision MAXO:0000004 (suggested)
  • Immune checkpoint inhibitor therapy MAXO:0001527 (suggested)

(MAXO IDs are suggested; the retrieved sources do not contain explicit MAXO mappings.)


13. Prevention

13.1 Primary prevention

Risk-factor modification (tobacco/alcohol reduction) is implied by the strong risk-factor association described in clinical guidance (sahu2023imagingrecommendationsfor pages 1-2).

13.2 Secondary prevention (high-risk surveillance)

Plummer–Vinson syndrome is consistently described as carrying malignancy risk that warrants surveillance: * PVS review abstract: “the risk of malignancy warrants long-term surveillance” (lo2019plummervinsonsyndromeimproving pages 1-2). * A PVS-focused excerpt notes “Surveillance endoscopy can be performed yearly, though no definitive recommendation exists” (patil2023endoscopicsubmucosaldissection pages 2-4).


14. Other species / natural disease

No naturally occurring postcricoid-region cancer analogs in other species were identified in the retrieved evidence set.


15. Model organisms

No postcricoid-region–specific experimental animal models were identified in the retrieved evidence set; mechanistic studies are therefore typically extrapolated from broader HNSCC models (cell lines, xenografts/PDX), but this is a current evidence gap in this retrieval (afshari2023potentialalternativetherapeutic pages 1-2).


Notes on evidence gaps and limitations

  • Postcricoid-region–specific molecular profiling, differential diagnosis, and model organism literature were not retrieved at depth in this run; much of the molecular discussion necessarily relies on broader HNSCC/HSCC evidence (afshari2023potentialalternativetherapeutic pages 1-2, shirima2024epithelial‑derivedheadand pages 3-4).
  • Several modern immunotherapy studies relevant to hypopharyngeal SCC exist beyond 2024; however, the highest-priority 2023–2024 organ-preservation chemoimmunotherapy trial evidence in this set is NCT04156698 / Nature Communications 2024 (NCT04156698 chunk 1).

Key URLs (as retrieved)

  • Mousavi et al., 2024 (Frontiers in Oncology; Sep 2024): https://doi.org/10.3389/fonc.2024.1398063 (mousavi2024globalepidemiologyand pages 1-2)
  • Sahu et al., 2023 (Indian J Med Paediatr Oncol; Jan 2023): https://doi.org/10.1055/s-0042-1759504 (sahu2023imagingrecommendationsfor pages 1-2)
  • Katano & Yamashita, 2024 (Eur Arch Otorhinolaryngol; May 2024): https://doi.org/10.1007/s00405-024-08722-w (katano2024earlystagehypopharyngealsquamous pages 1-2)
  • Lin et al., 2023 (Frontiers in Oncology; Mar 2023): https://doi.org/10.3389/fonc.2023.1109417 (lin2023survivalanalysesof pages 1-2)
  • Lo et al., 2019 (J Multidiscip Healthc; Jun 2019): https://doi.org/10.2147/jmdh.s180410 (lo2019plummervinsonsyndromeimproving pages 1-2)
  • Patil et al., 2023 (J Digestive Endoscopy; Dec 2023): https://doi.org/10.1055/s-0042-1759510 (patil2023endoscopicsubmucosaldissection pages 1-2)
  • NCT04156698: https://clinicaltrials.gov/study/NCT04156698 (NCT04156698 chunk 1)
  • NCT06039631: https://clinicaltrials.gov/study/NCT06039631 (NCT06039631 chunk 1)

References

  1. (glastonbury2020headandneck pages 1-2): Christine M. Glastonbury. Head and neck squamous cell cancer: approach to staging and surveillance. IDKD Springer Series, pages 215-222, Feb 2020. URL: https://doi.org/10.1007/978-3-030-38490-6_17, doi:10.1007/978-3-030-38490-6_17. This article has 46 citations.

  2. (mousavi2024globalepidemiologyand pages 1-2): Seyed Ehsan Mousavi, Mehran Ilaghi, Yasaman Mirzazadeh, Alireza Mosavi Jarrahi, and Seyed Aria Nejadghaderi. Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from globocan 2020. Frontiers in Oncology, Sep 2024. URL: https://doi.org/10.3389/fonc.2024.1398063, doi:10.3389/fonc.2024.1398063. This article has 13 citations.

  3. (sahu2023imagingrecommendationsfor pages 5-8): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  4. (katano2024earlystagehypopharyngealsquamous pages 1-2): Atsuto Katano and Hideomi Yamashita. Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 gy in 35 fractions: a single-center study. European Archives of Oto-Rhino-Laryngology, 281:4401-4407, May 2024. URL: https://doi.org/10.1007/s00405-024-08722-w, doi:10.1007/s00405-024-08722-w. This article has 11 citations and is from a peer-reviewed journal.

  5. (mousavi2024globalepidemiologyand pages 2-3): Seyed Ehsan Mousavi, Mehran Ilaghi, Yasaman Mirzazadeh, Alireza Mosavi Jarrahi, and Seyed Aria Nejadghaderi. Global epidemiology and socioeconomic correlates of hypopharyngeal cancer in 2020 and its projection to 2040: findings from globocan 2020. Frontiers in Oncology, Sep 2024. URL: https://doi.org/10.3389/fonc.2024.1398063, doi:10.3389/fonc.2024.1398063. This article has 13 citations.

  6. (sahu2023imagingrecommendationsfor pages 1-2): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  7. (sahu2023imagingrecommendationsfor pages 2-3): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  8. (katano2024earlystagehypopharyngealsquamous pages 2-5): Atsuto Katano and Hideomi Yamashita. Early-stage hypopharyngeal squamous cell carcinoma treated with radical radiotherapy at a uniform dose of 70 gy in 35 fractions: a single-center study. European Archives of Oto-Rhino-Laryngology, 281:4401-4407, May 2024. URL: https://doi.org/10.1007/s00405-024-08722-w, doi:10.1007/s00405-024-08722-w. This article has 11 citations and is from a peer-reviewed journal.

  9. (lin2023survivalanalysesof pages 1-2): Tian-Yun Lin, Tsung-Lun Lee, Yen-Bin Hsu, Shyh-Kuan Tai, Ling-Wei Wang, Muh-Hwa Yang, and Pen-Yuan Chu. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1109417, doi:10.3389/fonc.2023.1109417. This article has 10 citations.

  10. (lin2023survivalanalysesof pages 2-3): Tian-Yun Lin, Tsung-Lun Lee, Yen-Bin Hsu, Shyh-Kuan Tai, Ling-Wei Wang, Muh-Hwa Yang, and Pen-Yuan Chu. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma. Frontiers in Oncology, Mar 2023. URL: https://doi.org/10.3389/fonc.2023.1109417, doi:10.3389/fonc.2023.1109417. This article has 10 citations.

  11. (patil2023endoscopicsubmucosaldissection pages 1-2): Gaurav Patil, Amol Vadgaonkar, Ankit Dalal, Sanil Parekh, Animesh Shah, Poorva Haridas, Prajakta Gupte, Sehajad Vora, and Amit Maydeo. Endoscopic submucosal dissection for esophageal squamous cell high-grade dysplasia in a patient with plummer vinson syndrome. Journal of Digestive Endoscopy, 14:051-055, Dec 2023. URL: https://doi.org/10.1055/s-0042-1759510, doi:10.1055/s-0042-1759510. This article has 1 citations.

  12. (lo2019plummervinsonsyndromeimproving pages 5-6): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  13. (patil2023endoscopicsubmucosaldissection pages 2-4): Gaurav Patil, Amol Vadgaonkar, Ankit Dalal, Sanil Parekh, Animesh Shah, Poorva Haridas, Prajakta Gupte, Sehajad Vora, and Amit Maydeo. Endoscopic submucosal dissection for esophageal squamous cell high-grade dysplasia in a patient with plummer vinson syndrome. Journal of Digestive Endoscopy, 14:051-055, Dec 2023. URL: https://doi.org/10.1055/s-0042-1759510, doi:10.1055/s-0042-1759510. This article has 1 citations.

  14. (lo2019plummervinsonsyndromeimproving pages 2-3): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  15. (NCT04156698 chunk 1): Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma. Eye & ENT Hospital of Fudan University. 2020. ClinicalTrials.gov Identifier: NCT04156698

  16. (NCT06039631 chunk 1): Yu Wang. Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer. Fudan University. 2023. ClinicalTrials.gov Identifier: NCT06039631

  17. (OpenTargets Search: hypopharyngeal carcinoma,head and neck squamous cell carcinoma): Open Targets Query (hypopharyngeal carcinoma,head and neck squamous cell carcinoma, 13 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  18. (li2026novellaryngealpreservation pages 1-2): Xuexin Li, Xiaoran Zhang, Yun Lin, Yan Ma, Zheng Jiang, Dapeng Lei, Xinliang Pan, and Jun Liu. Novel laryngeal preservation technique in postcricoid hypopharyngeal carcinoma: a case-series study. BMC Surgery, Mar 2026. URL: https://doi.org/10.1186/s12893-026-03586-9, doi:10.1186/s12893-026-03586-9. This article has 0 citations and is from a peer-reviewed journal.

  19. (lo2019plummervinsonsyndromeimproving pages 1-2): Kevin Bryan Lo, Jeri Albano, Naemat Sandhu, and Nellowe Candelario. Plummer-vinson syndrome: improving outcomes with a multidisciplinary approach. Journal of Multidisciplinary Healthcare, 12:471-477, Jun 2019. URL: https://doi.org/10.2147/jmdh.s180410, doi:10.2147/jmdh.s180410. This article has 35 citations and is from a peer-reviewed journal.

  20. (NCT06957938 chunk 2): Yu Wang. Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma. Fudan University. 2025. ClinicalTrials.gov Identifier: NCT06957938

  21. (shirima2024epithelial‑derivedheadand pages 3-4): Charles Shirima, Coralia Bleotu, Demetrios Spandidos, Adel El‑Naggar, Gratiela Gradisteanu Pircalabioru, and Ioannis Michalopoulos. Epithelial‑derived head and neck squamous tumourigenesis (review). Oncology Reports, Aug 2024. URL: https://doi.org/10.3892/or.2024.8800, doi:10.3892/or.2024.8800. This article has 12 citations and is from a peer-reviewed journal.

  22. (afshari2023potentialalternativetherapeutic pages 1-2): Keihan Afshari and Karpal Singh Sohal. Potential alternative therapeutic modalities for management head and neck squamous cell carcinoma: a review. Cancer Control : Journal of the Moffitt Cancer Center, Apr 2023. URL: https://doi.org/10.1177/10732748231185003, doi:10.1177/10732748231185003. This article has 13 citations.

  23. (sahu2023imagingrecommendationsfor media 624946c3): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  24. (sahu2023imagingrecommendationsfor media dd0e55cc): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  25. (sahu2023imagingrecommendationsfor media 9d694104): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  26. (sahu2023imagingrecommendationsfor media 0adf3cdb): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  27. (sahu2023imagingrecommendationsfor media ea5671f7): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  28. (sahu2023imagingrecommendationsfor media 2fc9a3ce): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.

  29. (sahu2023imagingrecommendationsfor pages 10-12): Arpita Sahu, Abhishek Mahajan, Delnaz Palsetia, Richa Vaish, Sarbani Ghosh Laskar, Jyoti Kumar, Namita Kamath, Ashu Seith Bhalla, Diva Shah, Amit Sahu, Ujjwal Agarwal, Aditi Venkatesh, Suman Kumar Ankathi, Amit Janu, Vasundhara Patil, Tejas H. Kapadia, Munita Bal, Shwetabh Sinha, Kumar Prabhash, and A. K. Dcruz. Imaging recommendations for diagnosis, staging and management of larynx and hypopharynx cancer. Indian Journal of Medical and Paediatric Oncology, 44:054-065, Jan 2023. URL: https://doi.org/10.1055/s-0042-1759504, doi:10.1055/s-0042-1759504. This article has 15 citations.